OMC
STLN

Old Mission Capital’s Starling Oncology STLN Stock Holding History

Old Mission Capital’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-52,740
Closed -$29K – 1569
2023
Q2 		$29K Buy
+52,740
New +$27.9K ﹤0.01% 1198

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TAS
TIFF Advisory Services Radnor, Pennsylvania $408M AUM 20.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

Old Mission Capital's STLN Position: Q3 2023 in Review

Old Mission Capital sold out of Starling Oncology (STLN) in Q3 2023, closing a stake of 52,740 shares — an estimated $29K sold.

Old Mission Capital first reported a position in STLN in Q2 2023 and held it in 1 quarter. The position peaked at $29K in Q2 2023. 36 funds tracked by Wall St. Rank hold STLN as of Q3 2023.

  • Old Mission Capital reported no remaining Starling Oncology position as of Q3 2023 after selling out during the quarter.
  • Old Mission Capital sold 52,740 Starling Oncology shares in Q3 2023, an estimated $29K.
  • Old Mission Capital first reported a position in Starling Oncology in Q2 2023 and held it in 1 quarter.
  • Old Mission Capital's Starling Oncology position peaked at $29K in Q2 2023.
  • 36 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2023.

Based on Old Mission Capital's 13F filing for Q3 2023, filed 15 Nov 2023.